Literature DB >> 30839208

Proteasome Activation as a New Therapeutic Approach To Target Proteotoxic Disorders.

Evert Njomen1, Jetze J Tepe1.   

Abstract

Proteasomes are multienzyme complexes that maintain protein homeostasis (proteostasis) and important cellular functions through the degradation of misfolded, redundant, and damaged proteins. It is well established that aging is associated with the accumulation of damaged and misfolded proteins. This phenomenon is paralleled by declined proteasome activity. When the accumulation of redundant proteins exceed degradation, undesirable signaling and/or aggregation occurs and are the hallmarks of neurodegenerative diseases and many cancers. Thus, increasing proteasome activity has been recognized as a new approach to delay the onset or ameliorate the symptoms of neurodegenerative and other proteotoxic disorders. Enhancement of proteasome activity has many therapeutic potentials but is still a relatively unexplored field. In this perspective, we review current approaches, genetic manipulation, posttranslational modification, and small molecule proteasome agonists used to increase proteasome activity, challenges facing the field, and applications beyond aging and neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30839208      PMCID: PMC6745699          DOI: 10.1021/acs.jmedchem.9b00101

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  166 in total

1.  Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown.

Authors:  A F Kisselev; T N Akopian; V Castillo; A L Goldberg
Journal:  Mol Cell       Date:  1999-09       Impact factor: 17.970

Review 2.  Themes and variations on ubiquitylation.

Authors:  A M Weissman
Journal:  Nat Rev Mol Cell Biol       Date:  2001-03       Impact factor: 94.444

3.  Fibroblast cultures from healthy centenarians have an active proteasome.

Authors:  N Chondrogianni; I Petropoulos; C Franceschi; B Friguet; E S Gonos
Journal:  Exp Gerontol       Date:  2000-09       Impact factor: 4.032

Review 4.  The 26S proteasome: a molecular machine designed for controlled proteolysis.

Authors:  D Voges; P Zwickl; W Baumeister
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

Review 5.  Mechanisms underlying ubiquitination.

Authors:  C M Pickart
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

6.  MHC class I antigen processing of an adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells.

Authors:  A J Sijts; S Standera; R E Toes; T Ruppert; N J Beekman; P A van Veelen; F A Ossendorp; C J Melief; P M Kloetzel
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

7.  The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study.

Authors:  M Groll; W Heinemeyer; S Jäger; T Ullrich; M Bochtler; D H Wolf; R Huber
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

8.  Impaired proteasome function in Alzheimer's disease.

Authors:  J N Keller; K B Hanni; W R Markesbery
Journal:  J Neurochem       Date:  2000-07       Impact factor: 5.372

9.  Inhibition of the ubiquitin-proteasome system in Alzheimer's disease.

Authors:  Y A Lam; C M Pickart; A Alban; M Landon; C Jamieson; R Ramage; R J Mayer; R Layfield
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

10.  Structural basis for the activation of 20S proteasomes by 11S regulators.

Authors:  F G Whitby; E I Masters; L Kramer; J R Knowlton; Y Yao; C C Wang; C P Hill
Journal:  Nature       Date:  2000-11-02       Impact factor: 49.962

View more
  17 in total

1.  Regulation of Autophagic Flux by the 20S Proteasome.

Authors:  Evert Njomen; Jetze J Tepe
Journal:  Cell Chem Biol       Date:  2019-07-18       Impact factor: 8.116

2.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

3.  Small Molecule 20S Proteasome Enhancer Regulates MYC Protein Stability and Exhibits Antitumor Activity in Multiple Myeloma.

Authors:  Evert Njomen; Allison Vanecek; Theresa A Lansdell; Ya-Ting Yang; Peter Z Schall; Christi M Harris; Matthew P Bernard; Daniel Isaac; Omar Alkharabsheh; Anas Al-Janadi; Matthew B Giletto; Edmund Ellsworth; Catherine Taylor; Terence Tang; Sarah Lau; Marc Bailie; Jamie J Bernard; Vilma Yuzbasiyan-Gurkan; Jetze J Tepe
Journal:  Biomedicines       Date:  2022-04-19

4.  Peptidomimetics Based on C-Terminus of Blm10 Stimulate Human 20S Proteasome Activity and Promote Degradation of Proteins.

Authors:  Katarzyna Cekała; Karolina Trepczyk; Daria Sowik; Przemysław Karpowicz; Artur Giełdoń; Julia Witkowska; Małgorzata Giżyńska; Elżbieta Jankowska; Ewa Wieczerzak
Journal:  Biomolecules       Date:  2022-06-02

5.  Nicotinamide phosphoribosyltransferase inhibitor ameliorates mouse aging-induced cognitive impairment.

Authors:  Min Zeng; Tao-Feng Wei; Cong Chen; Chen Shen; Tong-Yao Gao; Xian Xie; Ming Wu; Yun-Bi Lu; Wei-Ping Zhang
Journal:  J Cereb Blood Flow Metab       Date:  2021-04-04       Impact factor: 6.200

6.  Dihydroquinazolines enhance 20S proteasome activity and induce degradation of α-synuclein, an intrinsically disordered protein associated with neurodegeneration.

Authors:  Taylor J Fiolek; Christina L Magyar; Tyler J Wall; Steven B Davies; Molly V Campbell; Christopher J Savich; Jetze J Tepe; R Adam Mosey
Journal:  Bioorg Med Chem Lett       Date:  2021-01-27       Impact factor: 2.823

Review 7.  Methods for the discovery of small molecules to monitor and perturb the activity of the human proteasome.

Authors:  Marianne E Maresh; Andres F Salazar-Chaparro; Darci J Trader
Journal:  Future Med Chem       Date:  2020-12-04       Impact factor: 3.808

Review 8.  Synergistic effects of brain injury and aging: common mechanisms of proteostatic dysfunction.

Authors:  Janani Saikumar; Nancy M Bonini
Journal:  Trends Neurosci       Date:  2021-07-20       Impact factor: 16.978

9.  Rpt2 proteasome subunit reduction causes Parkinson's disease like symptoms in Drosophila.

Authors:  Iván Fernández-Cruz; Iván Sánchez-Díaz; Verónica Narváez-Padilla; Enrique Reynaud
Journal:  IBRO Rep       Date:  2020-07-11

10.  Brain Transcriptome Analysis Links Deficiencies of Stress-Responsive Proteins to the Pathomechanism of Kii ALS/PDC.

Authors:  Satoru Morimoto; Mitsuru Ishikawa; Hirotaka Watanabe; Miho Isoda; Masaki Takao; Shiho Nakamura; Fumiko Ozawa; Yoshifumi Hirokawa; Shigeki Kuzuhara; Hideyuki Okano; Yasumasa Kokubo
Journal:  Antioxidants (Basel)       Date:  2020-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.